October 31, 2008
Large-Scale Survey Reveals Low Sexual Desire Most Common Distressing Female Sexual Problem, Affecting Up to One in 10 WomenOctober 7, 2008
New Survey Uncovers Critical Need for Education on Key Issues in Parkinson’s Disease ManagementOctober 5, 2008
Landmark COPD Trial Uplift® Shows Spiriva® Handihaler® Sustained Lung Function Improvements Over Four YearsSeptember 23, 2008
Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFTSeptember 2, 2008
Boehringer Ingelheim Earns Top Marks In 2009 Corporate Equality IndexAugust 31, 2008
TRANSCEND™ Trial Results Presented at European Society of Cardiology Congress and Published in The LancetJune 24, 2008
New Aptivus® (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV PatientsMay 14, 2008
PRoFESS® Results Announced at XVII European Stroke ConferenceMay 7, 2008
Boehringer Ingelheim Committed to Advancing the Science of Hypoactive Sexual Desire Disorder April 29 , 2008
Second Chances Study Shows Most Stroke Survivors "Very Satisfied" with their Overall Quality of Life March 31, 2008
Landmark ONTARGET™ trial demonstrates Micardis® is equally effective as ramipril, with fewer discontinuations, in a broad high-risk cardiovascular population February 19, 2008
Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA "Seal Of Approval"January 17, 2008
Boehringer Ingelheim announces enrollment is complete for the largest atrial fibrillation outcomes trial - The RE-LY™ Study